These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30459283)

  • 1. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
    Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
    Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.
    Dedoni S; Olianas MC; Onali P
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
    Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
    Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
    Uçkun E; Siaw JT; Guan J; Anthonydhason V; Fuchs J; Wolfstetter G; Hallberg B; Palmer RH
    J Mol Biol; 2021 Sep; 433(19):167158. PubMed ID: 34273398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
    Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
    Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.
    Li J; Wang Y; Li L; Or PM; Wai Wong C; Liu T; Ho WLH; Chan AM
    Mol Oncol; 2021 Aug; 15(8):2011-2025. PubMed ID: 33932101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.
    Takagi D; Tatsumi Y; Yokochi T; Takatori A; Ohira M; Kamijo T; Kondo S; Fujii Y; Nakagawara A
    Cancer Sci; 2013 May; 104(5):563-72. PubMed ID: 23360421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
    Del Grosso F; De Mariano M; Passoni L; Luksch R; Tonini GP; Longo L
    BMC Cancer; 2011 Dec; 11():525. PubMed ID: 22192458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
    Zhang G; Scarborough H; Kim J; Rozhok AI; Chen YA; Zhang X; Song L; Bai Y; Fang B; Liu RZ; Koomen J; Tan AC; Degregori J; Haura EB
    Sci Signal; 2016 Oct; 9(450):rs12. PubMed ID: 27811184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth.
    Lai WY; Chuang TP; Borenäs M; Lind DE; Hallberg B; Palmer RH
    Cell Death Differ; 2024 Jul; 31(7):910-923. PubMed ID: 38858548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells.
    Carew RM; Browne MB; Hickey FB; Brazil DP
    FEBS J; 2011 Sep; 278(18):3370-80. PubMed ID: 21777391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
    Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
    Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.
    Alshareef A; Gupta N; Zhang HF; Wu C; Haque M; Lai R
    Sci Rep; 2017 Dec; 7(1):16863. PubMed ID: 29203817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.